Premium
Elevated serum levels of soluble ICAM‐1 in non‐Hodgkin’s lymphomas correlate with tumour burden, disease activity and other prognostic markers
Author(s) -
Christiansen Ilse,
Gidlöf Cecilia,
Kälkner KarlMichael,
Hagberg Hans,
Bennmarker Helge,
Tötterman Thomas
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.00377.x
Subject(s) - orosomucoid , erythrocyte sedimentation rate , medicine , beta 2 microglobulin , lactate dehydrogenase , thymidine kinase , gastroenterology , disease , lymphoma , albumin , immunology , glycoprotein , biology , enzyme , biochemistry , virus , microbiology and biotechnology , herpes simplex virus
The serum levels of soluble ICAM‐1 (CD54) were significantly elevated in patients with non‐Hodgkin’s lymphomas (NHL, n = 127) and hairy cell leukaemia (HCL, n = 15) compared with healthy controls ( n = 31). In high‐grade malignant NHL ( n = 79) the sICAM‐1 levels correlated with the tumour mass as reflected in the Ann Arbor staging system but not with bulky disease. Further, the sICAM‐1 levels correlated with disease activity as reflected by the presence of B symptoms and with other known prognostic markers, in particular serum thymidine kinase (sTK). In patients with low‐grade malignant NHL ( n = 48) a trend towards higher serum levels of sICAM‐1 was found in patients with advanced stage and B symptoms. In both low‐ and high‐grade malignant NHL, elevated levels of sICAM‐1 were associated with poorer overall and disease‐free survival. The present results indicate that sICAM‐1 levels have a prognostic power equal to that of other serum markers claimed to be of prognostic value in NHL, namely serum lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR), beta‐2‐microglobulin (β 2 m), serum thymidine kinase (sTK), albumin and orosomucoid. The cellular origin and the possible interactions between soluble and surface ICAM‐1 and its ligands needs further exploration.